Cabaletta Bio
CABA
68 hedge funds and large institutions have $180M invested in Cabaletta Bio in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 1 closing their positions.
1,300% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 1
50% more call options, than puts
Call options by funds: $835K | Put options by funds: $555K
24% more funds holding
Funds holding: 55 → 68 (+13)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
0.23% more ownership
Funds ownership: 67.22% → 67.45% (+0.23%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $202M → $180M (-$21.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.76M |
| 2 |
Millennium Management
New York
|
+$3.31M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$1.8M |
| 4 |
BlackRock
New York
|
+$1.19M |
| 5 |
EP
Eversept Partners
New York
|
+$939K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$8.33M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$4.73M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.7M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$315K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$150K |
CABA Hedge Fund Activity: Q1 2021 in Review
68 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q1 2021, worth a combined $180M — down 11% from $202M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CABA positions and 1 closed out — a net gain of 13 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $4.76M. The largest seller was Redmile Group, cutting an estimated $8.33M.
- 68 institutional investors held Cabaletta Bio (CABA) as of Q1 2021, up from 55 in Q4 2020.
- Funds reported $180M of Cabaletta Bio stock for Q1 2021, down 11% quarter-over-quarter.
- 14 funds opened new Cabaletta Bio positions in Q1 2021 and 1 closed out, a net change of +13 holders.
- The largest Cabaletta Bio buyer in Q1 2021 was Ikarian Capital, an estimated $4.76M added.
- The largest Cabaletta Bio seller in Q1 2021 was Redmile Group, an estimated $8.33M sold.
Based on aggregated 13F filings for Q1 2021.